Atrasentan hydrochloride Chemical Properties

storage temp. 

under inert gas (nitrogen or Argon) at 2-8°C

solubility 

Soluble in DMSO

form 

Powder

InChI

InChI=1/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/s3

InChIKey

IJFUJIFSUKPWCZ-FZVADPAUNA-N

SMILES

C1(=CC2=C(OCO2)C=C1)[C@@H]1[C@@H](C(=O)O)[C@H](C2C=CC(OC)=CC=2)N(CC(N(CCCC)CCCC)=O)C1.Cl |&1:9,10,14,r|

Atrasentan hydrochloride Usage And Synthesis

Description

Atrasentan Hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.

Uses

Atrasentan belongs to a pyrrolidine and benzodioxole derivative. It is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in the inhibition of endothelin-induced angiogenesis and tumor cell proliferation. Its potential therapeutic uses include the treatment of diabetic nephropathies and as an antineoplastic agent.

Biological Activity

Atrasentan is a selective endothelin ETA receptor antagonist with an IC50 of 0.2 nM for ETA compared to 190 nM for ETB receptors. It blocks blocks endothelin induced cell proliferation, and has been investigated as a possible treatment for prostate cancer, and more recently for therapy for diabetic kidney disease.

Atrasentan hydrochloride(195733-43-8)Related Product Information

• 1,4-Dioxane
• Benzo[a]pyrene
• Topotecan hydrochloride
• Tamsulosin hydrochloride
• Selenium dioxide
• Tamsulosin hydrochloride
• atrasentan
• DIOXOPROMETHAZINE
• Atrasentan hydrochloride